Drug intelligence / Profile preview

JW-0107

Development stage: Phase 1
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JW-0107 is an investigational small molecule drug being developed by JW Pharmaceutical. It is administered orally as a film-coated tablet and is currently under development for the treatment of essential hypertension and dyslipidemia. The precise mechanism of action has not been publicly disclosed, and the primary indications are cardiovascular-related conditions.

Beyond the preview

Go deeper on JW-0107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW-0107.

Explore the full profile